Occidental, ZoomInfo, GEHC, Opus, Medtronic Trending by Analysts

Analysts are intrested in these 5 stocks: ( (OXY) ), ( (GTM) ), ( (GEHC) ), ( (IRD) ) and ( (MDT) ). Here is a breakdown of their recent ratings and the rationale behind them.

Occidental Petroleum is back on analysts’ radar as Neil Mehta shifts his view from Sell to Hold, reflecting a company that has moved from aggressive deal-making to what he calls “investment mode to FCF harvest.” The upgrade comes after meaningful debt reduction, lower capital intensity, and a sharper focus on efficiency, though he still sees only modest upside to his $64 target compared with more favored peers.

For investors, that means OXY looks more like a steady cash generator than a high‑octane growth story, with risk and reward now more balanced than in the past. Mehta points out that at current prices the stock offers about 5% upside over 12 months, less than Buy‑rated names like Diamondback Energy and ConocoPhillips, suggesting OXY may appeal more to those seeking stability than big gains.

ZoomInfo Technologies, trading under ticker GTM, faces a tougher narrative as Surinder Thind cuts the stock from Buy to Hold and slashes his price target from $12 to just $4. Thind now expects revenue to shrink in both 2026 and 2027 as the company shifts from traditional subscriptions to a usage-based model amid weakening demand and powerful AI-driven changes in customer behavior.

The analyst highlights a painful 12–18 month transition, including a major workforce reduction and a pivot to product-led growth, which could depress sales before any payoff. Still, he notes that strong free cash flow, rising margins from cost cuts, and share buybacks leave room for a sharp turnaround if growth stabilizes, making GTM a high‑uncertainty Hold rather than a broken story.

GE Healthcare Technologies (GEHC) gets a cautious vote of confidence as Graham Doyle moves his rating from Sell to Neutral, even while trimming his target price to $69. After a roughly 30% slide that took the stock back toward IPO levels, Doyle argues that worries over China, inflation, and product execution are now better baked into a valuation of about 12 times expected 2027 earnings.

However, he stresses that he still sees limited near‑term catalysts and forecasts profits below management guidance and consensus beyond 2026. Doyle prefers Philips for more immediate upside, and flags lingering questions on inflation resilience, China recovery, competition from generics, and the Flyrcado product ramp, positioning GEHC as a value name that may need time before sentiment truly improves.

Opus Genetics, ticker IRD, offers a very different kind of story as Lili (Aurélie) Nsongo opens coverage with a Buy rating and a $10 price target. The company develops gene therapies for inherited retinal disorders, which are a major cause of blindness, and Nsongo sees a compelling risk/reward profile with multiple shots on goal.

She points to upcoming data for lead program OPGxBEST1, which could jump quickly into Phase 3 and support a sizable market opportunity, as well as additional candidates like OPGxLCA5 and partnered asset Ryzumvi that bring potential royalties and milestones. Strong cash runway into 2029 and regulatory tailwinds in eye diseases further support the bullish view, making Opus a speculative but promising play for investors comfortable with biotech risk.

Medtronic rounds out the list as David Roman reinstates coverage at Neutral with a $84 target, implying mid‑single‑digit upside from current levels. He sees the stock trading at about a 10% discount to large‑cap medtech peers, which he believes is fair given Medtronic’s steady but not spectacular organic growth around 5% and more limited margin expansion.

Roman’s base case aligns with consensus earnings through 2027 but turns more cautious further out, reflecting a risk-adjusted stance on pipeline products like Symplicity, Atlaviva, and Hugo even as he assumes meaningful contributions from Affera. For investors, Medtronic looks like a balanced risk/reward proposition where better execution could unlock upside, but clear catalysts still need to emerge before the stock can break decisively higher.